AI assistant
Insight Molecular Diagnostics Inc. — Director's Dealing 2017
Feb 22, 2017
34238_dirs_2017-02-22_18b72dab-c0b8-42de-a2f8-79908e9af30a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2017-02-17
Reporting Person: HESTERBERG LYNDAL K. (Sr VP, Research & Development)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-02-17 | Option to Purchase Common Stock | $4.70 | A | 14400 | Acquired | 2027-02-16 | Common Stock (14400) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Option to Purchase Common Stock | $4.05 | 2026-10-31 | Common Stock (125000) | 125000 | Direct |
| Option to Purchase Common Stock | $3.06 | 2026-02-15 | Common Stock (25000) | 25000 | Direct |
Footnotes
F1: One quarter of the options shall vest on February 16, 2018, subject to the completion of 12 months of continuous employment from the date of grant, and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant.
F2: One quarter of the options shall vest on October 31, 2017, subject to the completion of 12 months of continuous employment from the date of grant on November 1, 2016, and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant.
F3: One quarter of the options vested on February 15, 2017 and one quarter shall vest on February 15, 2018, and the balance shall vest upon the attainment of certain product development milestones, in each case depending upon continuous employment by the Company.